展望"十五五"，天津滨海高新区相关领导表示，天津滨海高新区将锚定"全国领先的生物科技与生物制造产 业高地"目标，统筹推进华苑科创先导区与渤龙湖先进制造业承载区联动发展，建强京津冀特色"细胞 谷"和"中国脑机谷"两大科创和产业高地，聚焦创新药物、医疗器械、细胞治疗、脑机交互、医药服务五大 核心产业，前瞻布局生物制造等多个潜力产业领域，努力将天津滨海高新区生物医药产业打造成为具有全国 影响力、全球竞争力的标志性产业集群。 天津滨海高新区将牢牢把握"十五五"谋篇布局的历史机遇，凝心聚力推动生物医药产业链与创新链深度融 合，以政策为引领、平台为支撑、生态为保障，奋力实现生物医药产业高质量发展，为区域经济转型升级注 入强劲动能。(中国化工报曲照贵) 天津滨海高新区管委会有关领导在发布会上介绍了天津滨海高新区生物医药产业"十四五"期间发展情况。他 表示，"十四五"时期，天津滨海高新区将生物医药产业作为核心主导产业，推进科技创新与产业创新融合， 产值年均增长率达16%，在全国生物医药产业园区排名中连续3年保持全国前列。 "十四五"期间，天津滨海高新区以科技创新引领新质生产力发展、带动生物医药产业"量质齐升"。构建国家 重点 ...

Group 1 - The core point of the news is that shareholders of Priss (SZ 301257) plan to reduce their holdings in the company through centralized bidding transactions within three months after the announcement [1][2] - The shareholder Zibo Hongrun Yingke Venture Capital Partnership holds 6,500 shares, accounting for 0.0082% of the total share capital, and plans to reduce its holdings by the same amount [1] - The shareholder Shihezi Ruixin Equity Investment Partnership holds approximately 6.4 million shares, accounting for 8.0977% of the total share capital, and plans to reduce its holdings by up to 73,100 shares, which is 0.0925% of the total share capital [1] Group 2 - The company's financial director, Song Weihong, holds approximately 292,500 shares indirectly through Shihezi Ruixin and 3,250 shares directly, planning to reduce her total holdings by up to 73,900 shares, which is 0.0935% of the total share capital [2] - The planned reduction by Song Weihong does not exceed 25% of her total direct and indirect holdings [2] Group 3 - For the first half of 2025, Priss's revenue composition is entirely from the service industry, accounting for 100% [3] - As of the report, Priss has a market capitalization of 3.5 billion yuan [4]

Company Overview - Yifan Pharmaceutical's stock price increased by 2.14% on September 18, reaching 14.81 CNY per share, with a trading volume of 176 million CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 18.015 billion CNY [1] - The company was established on November 10, 2000, and went public on July 13, 2004. It is located in Lin'an District, Hangzhou, Zhejiang Province [1] - Yifan Pharmaceutical's main business includes the production and sale of active pharmaceutical ingredients and high polymer materials, with revenue composition as follows: proprietary pharmaceutical products (including imports) 75.52%, vitamins 11.47%, other pharmaceutical products 9.52%, high polymer materials 3.00%, and pharmaceutical services 0.49% [1] Financial Performance - For the first half of 2025, Yifan Pharmaceutical achieved operating revenue of 2.635 billion CNY, a year-on-year increase of 0.11%, and a net profit attributable to shareholders of 304 million CNY, representing a year-on-year growth of 19.91% [2] - The company has distributed a total of 1.328 billion CNY in dividends since its A-share listing, with 243 million CNY distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders of Yifan Pharmaceutical reached 42,900, an increase of 3.38% from the previous period, with an average of 19,634 circulating shares per person, a decrease of 3.27% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 25.5819 million shares, an increase of 2.4783 million shares from the previous period [3]